Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +433.33%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced earnings of $0.14, delivering a surprise of +158.33%.Over the last four quarters, the ...

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +67.87%. A quarter ago, it was expected that this physician practice management company would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the la ...

Core Viewpoint - Pulmonx reported better-than-expected quarterly earnings, with a revenue of $21.50 million, surpassing analyst estimates of $20.78 million, and an EPS of ($0.34), exceeding the consensus estimate of ($0.40) by $0.06 [1] Financial Performance - The company had a negative return on equity of 77.58% and a negative net margin of 61.91% [1] - The stock opened at $1.45, with a market cap of $59.81 million, a PE ratio of -1.03, and a beta of 0.07 [2] - The fifty-day simple moving average is $2.04, and the 200-day simple moving average is $1.83 [2] - The stock has a fifty-two week low of $1.31 and a high of $9.37 [2] Analyst Ratings - Weiss Ratings restated a "sell (e+)" rating, while Lake Street Capital decreased their price target from $8.00 to $4.00 with a "buy" rating [4] - D. Boral Capital reaffirmed a "buy" rating with a price objective of $14.00, and Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Currently, five analysts have rated the stock as "buy," four as "hold," and one as "sell," with an average price target of $6.81 [4] Institutional Activity - XTX Topco Ltd acquired a new stake worth about $149,000, and Norges Bank acquired a position valued at approximately $392,000 [5] - Jane Street Group LLC increased its stake by 3,328.7%, now owning 88,631 shares valued at $230,000 [5] - Bank of America Corp DE boosted its position by 556.6%, owning 481,268 shares worth $1,246,000 [5] - Institutional investors and hedge funds own 91.04% of the company's stock [5] Company Overview - Pulmonx Corporation focuses on bronchoscopic lung volume reduction for patients with severe emphysema, with its flagship product being the Zephyr® Endobronchial Valve System [6] - The Zephyr Valve received CE mark approval in Europe in 2008 and FDA approval in the U.S. in 2018, gaining adoption in leading respiratory and thoracic centers [8]

Core Insights - American Well Corporation (AMWL) reported a quarterly loss of $1.74 per share, which was better than the Zacks Consensus Estimate of a loss of $1.83, and improved from a loss of $2.87 per share a year ago, resulting in an earnings surprise of +4.92% [1] - The company generated revenues of $56.29 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.53%, although this represents a decline from year-ago revenues of $61.05 million [2] - American Well has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in earnings performance [2] Financial Performance - The company has experienced a significant decline in share price, losing approximately 29.8% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.94, with projected revenues of $55.3 million, and for the current fiscal year, the estimate is -$6.13 on revenues of $247.42 million [7] Industry Outlook - The Medical Info Systems industry, to which American Well belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact American Well's stock performance [5][6]

Group 1: Penny Stocks Overview - Five penny stocks to watch include Beyond Meat, Strive, VSee Health, Pulmonx, and Datavault AI, identified by MarketBeat's stock screener tool [2] - Penny stocks are defined as shares of very small or microcap companies trading at low per-share prices, traditionally under $1 but commonly under $5 in the U.S. [2] - These stocks often trade on over-the-counter markets, characterized by low liquidity, wide bid-ask spreads, high volatility, and a greater risk of price manipulation and loss [2] Group 2: Company Profiles - Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products across various platforms including beef, pork, and poultry, with distribution through grocery and foodservice channels [3] - Strive (Asset Entities Inc.) provides social media marketing and content delivery services, focusing on platforms like Discord and TikTok, and offers investment education and marketing services [4] - Pulmonx Corporation specializes in minimally invasive devices for chronic obstructive pulmonary diseases, offering products like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System [5] - Datavault AI Inc. operates data management and supercomputer platforms, providing data technology and software solutions, previously known as WiSA Technologies, Inc. [6]

Group 1 - Celestica Inc. reported third-quarter earnings of $1.58 per share, exceeding the analyst estimate of $1.47 per share [1] - The company's quarterly revenue reached $3.19 billion, surpassing the Street estimate of $3.01 billion [1] - Following the positive financial results, Celestica shares surged 8.3% to $326.87 in pre-market trading [1] Group 2 - TEN Holdings, Inc. gained 89.2% to $0.5294 in pre-market trading after a 5% increase on Monday [4] - Freight Technologies, Inc. surged 65.1% to $2.03 in pre-market trading after adding 5% on Monday [4] - J-Star Holding Co., Ltd rose 48% to $1.270 in pre-market trading [4] - Reliance Global Group, Inc. surged 48% to $1.41 in pre-market trading after completing the purchase of Solana and reaffirming a special cash dividend of $0.03 per share for December [4] - Founder Group Limited rose 40.3% to $0.4947 in pre-market trading after gaining 5% on Monday [4] - AtlasClear Holdings, Inc. gained 29% to $0.4893 in pre-market trading due to a 49% increase in net income at its subsidiary [4] - 374Water Inc. gained 22.3% to $0.4733 in pre-market trading after a 15% dip on Monday [4] - Pulmonx Corporation rose 16.7% to $1.82 in pre-market trading following management transition and preliminary third-quarter revenue announcement [4] Group 3 - Co-Diagnostics, Inc. tumbled 13.5% to $1.09 in pre-market trading after a significant 259% jump on Monday [4] - Rambus Inc. declined 14.3% to $97.29 in pre-market trading after announcing downbeat quarterly earnings [4] - Royalty Management Holding Corp fell 12.9% to $2.50 in pre-market trading after an 8% decline on Monday [4] - GoldMining Inc fell 9.7% to $1.21 in pre-market trading after a decline of more than 5% on Monday [4] - Galaxy Digital Inc dipped 8.8% to $37.00 in pre-market trading following a private offering of $1 billion in exchangeable senior notes [4]

Group 1: Market Movements - Several healthcare and biotech stocks experienced significant gains in after-hours trading, influenced by earnings updates, executive appointments, and capital market activities [1] Group 2: Company-Specific Updates - Pulmonx Corp. (LUNG) saw a surge of 33.33% to $2.08, announcing preliminary third-quarter 2025 revenue of approximately $21.5 million and a leadership change with Glen French reappointed as President and CEO [2] - Q32 Bio Inc. (QTTB) increased by 12.5% to $3.15, although no specific news was reported to explain this rise [3] - Universal Health Services Inc. (UHS) climbed 7.41% to $229.90 after reporting third-quarter results and revising its full-year 2025 operating forecast, alongside a $1.5 billion increase in its stock repurchase program [3] - X4 Pharmaceuticals Inc. (XFOR) gained 5.35% to close at $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses [4] - Greenwich LifeSciences Inc. (GLSI) advanced 5.41% to $10.32 with no new developments reported [5] - Cardiff Oncology, Inc. (CRDF) moved up 5.26% to $2.41, also without any accompanying news [5]

Core Viewpoint - Pulmonx Corporation is set to release its financial results for Q1 2025 on April 30, 2025, and will host a conference call to discuss these results [1]. Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3]. - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report, which are designed for patients with severe emphysema/COPD [3]. - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving the quality of life in patients with severe emphysema [3].

Company Overview - P3 Health Partners Inc. (PIII) shares increased by 8.9% to close at $9.79, supported by high trading volume, contrasting with a 5% gain over the past four weeks [1] - The company reported fourth quarter revenue of $371 million, marking a 7% year-over-year increase, and reaffirmed its 2025 revenue guidance of $1.35 billion to $1.5 billion, with expectations of achieving profitability this year [2] Earnings Expectations - The upcoming report for P3 Health Partners is expected to show a quarterly loss of $5 per share, reflecting a year-over-year change of -3025%, with revenues anticipated at $363.75 million, down 6.4% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 14.3% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - P3 Health Partners operates within the Zacks Medical Info Systems industry, where another company, Pulmonx Corporation (LUNG), experienced a 9.1% decline in its stock price, closing at $4.92, and has returned -30.6% over the past month [4] - Pulmonx's consensus EPS estimate for the upcoming report remains unchanged at -$0.37, representing a -2.8% change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [5]